Shots:

• The PALOMA-3 Trial involves assessing of Ibrance (palbociclib) + fulvestrant vs PBO + fulvestrant in women having HR+- HER2- metastatic breast cancer for 2L
• PALOMA-3 Trial results: mOS (34.9 vs 28.0 mos); mPFS (11.2 vs 4.6 mos); median CT (17.6 vs 8.8 mos.)
• Ibrance PO is CDKs 4 and 6 inhibitor indicated for HR+- HER2- advance or mBC and has been prescribed to 160-000 patients with approval in 85 countries worldwide

Ref: Pfizer | Image: Mgcop